About Q-Line Biotech Limited
Data last updated:
Q-Line Biotech Limited is a public limited company based in Lucknow, Uttar Pradesh, India. It operates in the medical equipment retail and distribution segment of the healthcare sector. It was incorporated on 10 November 2010 and has been in existence for over 16 years.
The company is registered with the Registrar of Companies (ROC), Uttar Pradesh, under CIN U74120UP2010PLC042528. Its GSTIN is 09AAFCP9672B1Z6 (Uttar Pradesh). The company holds 5 GST registrations, of which 4 are active. It is a listed company as per MCA records. Its shares are listed on NSE: QLINE.
The company has an authorised share capital of ₹25 Cr and a paid-up capital of ₹23.33 Cr. It was formerly known as Poct Services Private Limited and Sperogenx Lifesciences Private Limited. It is led by directors including Saurabh Garg (Managing Director) and Kuldeep Chowdhry (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 298 – 281 Transport Nagar Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, India – 226012.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹341.74 Cr, a growth of 8.9% compared to the previous year. For the same year it recorded a net profit of ₹56.48 Cr (net margin 16.5%) and EBITDA of ₹97.06 Cr (EBITDA margin 28.4%). The net worth stands at ₹246.2 Cr (up 29.6% YoY). Total assets are valued at ₹478.06 Cr (up 32.7% YoY).
The company has about 219 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Q-Line Biotech. As per MCA filings, the company has open charges of ₹269.76 Cr and satisfied charges of ₹25.81 Cr on record. Court records list 13 cases involving the company, including 6 filed by the company and 7 filed against it; 5 cases are pending. The company has 9 deals on record (3 funding rounds, 3 secondary share transfers, 1 rights issue), with disclosed funding of ₹28.82 Cr; the latest was in May 2026. The company has 3 MSME Form 1 returns on record between 2015 and 2024, listing 24 overdue payments to 23 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website poctservices.com.
Company details
Name history
Q-Line Biotech has undergone 3 name changes throughout its history. The company was previously known as Poct Services Private Limited, Sperogenx Lifesciences Private Limited, and Q-Line Biotech Limited. The current legal name is Q-Line Biotech Limited.
| Company Name | Status |
|---|---|
| Q-Line Biotech Limited | Current |
| Poct Services Private Limited | Previous |
| Sperogenx Lifesciences Private Limited | Previous |
CIN history
Q-Line Biotech has one previous CIN (Corporate Identification Number): U74120UP2010PTC042528. The current CIN is U74120UP2010PLC042528, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U74120UP2010PLC042528 | Current |
| U74120UP2010PTC042528 | Previous |
Contact details
Q-Line Biotech Limited's registered office is in Lucknow, Uttar Pradesh. Its website is poctservices.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address298 – 281 Transport Nagar Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, India – 226012
- IndustryHealthcare, Medical Equipment Retail & Distribution
To see the full contact details of Q-Line Biotech Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Q-Line Biotech operates one associated brand: Q-Line Biotech. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| IVD products are supplied to the diagnostic industry in India. | qlinebiotech.com |
Business activity
The main business activity of Q-Line Biotech is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Q-Line Biotech Limited, buy the company report.
Financials of Q-Line Biotech Limited
FY 2025-26 filings availableQ-Line Biotech Limited reported revenue of ₹341.74 Cr (up 8.9% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 342 | 314 | 204 | 183 |
| Revenue growth | +8.9% | +54.1% | +11.4% | - |
| EBITDA | 97.06 | 57.57 | 38.06 | 33.77 |
| EBITDA margin | +28.4% | +18.4% | +18.7% | +18.5% |
| Profit before tax | 72.55 | 44.18 | 30.59 | 29.86 |
| Net profit | 56.48 | 45.09 | 33.92 | 32.11 |
| Net profit margin | +16.5% | +14.4% | +16.7% | +17.6% |
| EPS (₹) | 34.79 | 178.61 | 218.70 | 203.79 |
| Balance sheet | ||||
| Total assets | 478 | 360 | 261 | 203 |
| Net worth | 246 | 190 | 162 | 127 |
| Total debt | 225 | 166 | 96.91 | 73.64 |
| Cash & bank | 76.44 | 47.03 | 29.96 | 90.02 |
| Net working capital | 263 | 170 | 120 | 127 |
| Cash flow | ||||
| Cash from operations | 16.38 | 17.21 | (24.18) | 24.97 |
| Cash from investing | (29.42) | (77.47) | (44.69) | (26.31) |
| Cash from financing | 41.64 | 53.18 | 16.99 | 26.40 |
| Particulars | Mar 2026 | Dec 2025 |
|---|---|---|
| Revenue | 109 | 88.62 |
| Other income | 1.62 | 1.41 |
| EBITDA | 31.96 | 29.13 |
| EBITDA margin | +29.2% | +32.9% |
| Depreciation | 4.49 | 2.21 |
| Interest | 6.08 | 5.03 |
| Profit before tax | 23.01 | 23.30 |
| Tax | 5.98 | 5.93 |
| Net profit | 17.03 | 17.37 |
| EPS (₹) | 0.00 | 0.00 |
| Metrics | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Income statement | ||
| Revenue | 341 | 313 |
| Revenue growth | +9.0% | - |
| EBITDA | 98.19 | 65.85 |
| EBITDA margin | +28.8% | +21.0% |
| Profit before tax | 74.21 | 66.52 |
| Net profit | 57.84 | 37.75 |
| Net profit margin | +17.0% | +12.1% |
| EPS (₹) | 34.99 | 300.93 |
| Balance sheet | ||
| Total assets | 467 | 354 |
| Net worth | 247 | 190 |
| Total debt | 213 | 160 |
| Cash & bank | 75.93 | 44.46 |
| Net working capital | 263 | 167 |
| Cash flow | ||
| Cash from operations | 20.97 | 21.81 |
| Cash from investing | (28.94) | (75.44) |
| Cash from financing | 36.35 | 46.50 |
Financial Statements
| Particulars | Mar 2026 | Dec 2025 |
|---|---|---|
| Revenue | 109 | 88.62 |
| Other income | 1.62 | 1.41 |
| EBITDA | 31.96 | 29.13 |
| EBITDA margin | +29.2% | +32.9% |
| Depreciation | 4.49 | 2.21 |
| Interest | 6.08 | 5.03 |
| Profit before tax | 23.01 | 23.30 |
| Tax | 5.98 | 5.93 |
| Net profit | 17.03 | 17.37 |
| EPS (₹) | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Revenue | 342 | 314 | 204 | 183 |
| Revenue growth | +8.9% | +54.1% | +11.4% | - |
| Other income | 5.70 | 8.80 | 2.80 | 2.08 |
| Total expenses | 245 | 256 | 166 | 149 |
| Employee cost | 0.00 | 27.23 | 20.52 | 18.88 |
| EBITDA | 97.06 | 57.57 | 38.06 | 33.77 |
| EBITDA margin | +28.4% | +18.4% | +18.7% | +18.5% |
| Depreciation | 10.79 | 7.32 | 3.93 | 2.14 |
| Interest | 19.42 | 14.87 | 6.34 | 3.85 |
| Profit before tax | 72.55 | 44.18 | 30.59 | 29.86 |
| Tax | 16.83 | 19.68 | 8.96 | 8.46 |
| Net profit | 56.48 | 45.09 | 33.92 | 32.11 |
| Net profit margin | +16.5% | +14.4% | +16.7% | +17.6% |
| EPS (₹) | 34.79 | 178.61 | 218.70 | 203.79 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Equity & liabilities | ||||
| Share capital | 16.28 | 1.58 | 1.58 | 1.58 |
| Reserves & surplus | 230 | 188 | 160 | 126 |
| Shareholders' funds (net worth) | 246 | 190 | 162 | 127 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 219 | 157 | 82.69 | 64.56 |
| Unsecured loans | 6.65 | 8.96 | 14.22 | 9.08 |
| Total debt | 225 | 166 | 96.91 | 73.64 |
| Total liabilities | 478 | 360 | 261 | 203 |
| Assets | ||||
| Gross block | 189 | 111 | 72.66 | 31.61 |
| Net block | 158 | 91.32 | 59.93 | 22.80 |
| Capital work in progress | 19.31 | 62.55 | 19.17 | 11.74 |
| Investments | 0.00 | 0.00 | 28.51 | 15.70 |
| Inventories | 94.96 | 90.21 | 105 | 43.59 |
| Sundry debtors | 126 | 82.60 | 26.44 | 33.06 |
| Cash & bank balances | 76.44 | 47.03 | 29.96 | 90.02 |
| Loans & advances | 46.84 | 45.08 | 36.89 | 9.44 |
| Total current assets | 344 | 265 | 199 | 176 |
| Total current liabilities | 80.62 | 95.27 | 78.46 | 48.80 |
| Net working capital | 263 | 170 | 120 | 127 |
| Total assets | 478 | 360 | 261 | 203 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Opening cash | 12.64 | 19.72 | 71.60 | 46.54 |
| Net cash from operating activities | 16.38 | 17.21 | (24.18) | 24.97 |
| Net cash from investing activities | (29.42) | (77.47) | (44.69) | (26.31) |
| Net cash from financing activities | 41.64 | 53.18 | 16.99 | 26.40 |
| Net change in cash | 28.60 | (7.08) | (51.88) | 25.06 |
| Closing cash | 76.44 | 47.03 | 29.96 | 90.02 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|---|
| Growth | ||||
| Sales growth | +8.9% | +54.1% | +11.4% | - |
| EBITDA growth | +68.6% | +51.3% | +12.7% | - |
| PBT growth | +64.2% | +44.4% | +2.4% | +9997.0% |
| Net income growth | +25.3% | +32.9% | +5.6% | - |
| Revenue CAGR (3Y) | +23.2% | - | - | - |
| EBITDA CAGR (3Y) | +42.2% | - | - | - |
| Profitability & leverage | ||||
| Net income margin | +16.3% | +7.8% | +10.6% | +11.7% |
| Return on capital employed | - | +24.5% | +15.9% | +16.6% |
| Return on net worth | - | +23.6% | +15.0% | +16.8% |
| Debt / equity | - | 0.75 | 0.59 | 0.58 |
| Long-term debt / equity | - | 0.33 | 0.17 | 0.11 |
| Interest cover | 22.51 | 29.59 | 18.58 | 12.17 |
| Efficiency & per share | ||||
| Fixed asset turnover | - | 3.41 | 3.91 | 5.78 |
| Inventory turnover | - | 3.21 | 2.74 | 4.19 |
| Debtors turnover | - | 5.76 | 6.85 | 5.53 |
| EPS (₹) | 34.79 | 178.61 | 218.70 | 203.79 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 1,206.00 | 1,027.39 | 808.67 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Revenue | 341 | 313 |
| Revenue growth | +9.0% | - |
| Other income | 5.73 | 22.57 |
| Total expenses | 243 | 247 |
| Employee cost | 7.78 | 6.13 |
| EBITDA | 98.19 | 65.85 |
| EBITDA margin | +28.8% | +21.0% |
| Depreciation | 10.78 | 6.93 |
| Interest | 18.93 | 14.97 |
| Profit before tax | 74.21 | 66.52 |
| Tax | 17.27 | 19.15 |
| Net profit | 57.84 | 37.75 |
| Net profit margin | +17.0% | +12.1% |
| EPS (₹) | 34.99 | 300.93 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Equity & liabilities | ||
| Share capital | 16.28 | 1.58 |
| Reserves & surplus | 231 | 188 |
| Shareholders' funds (net worth) | 247 | 190 |
| Secured loans | 213 | 157 |
| Unsecured loans | 0.03 | 2.46 |
| Total debt | 213 | 160 |
| Total liabilities | 467 | 354 |
| Assets | ||
| Gross block | 188 | 111 |
| Net block | 158 | 91.32 |
| Capital work in progress | 15.40 | 59.03 |
| Investments | 0.01 | 0.01 |
| Inventories | 94.76 | 90.21 |
| Sundry debtors | 127 | 82.78 |
| Cash & bank balances | 75.93 | 44.46 |
| Loans & advances | 46.21 | 44.30 |
| Total current assets | 344 | 262 |
| Total current liabilities | 80.35 | 95.21 |
| Net working capital | 263 | 167 |
| Total assets | 467 | 354 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Opening cash | 12.35 | 19.49 |
| Net cash from operating activities | 20.97 | 21.81 |
| Net cash from investing activities | (28.94) | (75.44) |
| Net cash from financing activities | 36.35 | 46.50 |
| Net change in cash | 28.38 | (7.14) |
| Closing cash | 75.93 | 44.46 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Growth | ||
| Sales growth | +9.0% | - |
| EBITDA growth | +49.1% | - |
| PBT growth | +11.6% | +9997.0% |
| Net income growth | +53.2% | - |
| Profitability & leverage | ||
| Net income margin | +16.7% | +15.1% |
| Return on capital employed | +22.7% | +20.8% |
| Return on net worth | +26.1% | +19.9% |
| Debt / equity | 0.85 | 0.84 |
| Long-term debt / equity | 0.39 | 0.43 |
| Interest cover | 21.66 | 25.41 |
| Efficiency & per share | ||
| Fixed asset turnover | 2.28 | 2.83 |
| Inventory turnover | 3.69 | 3.47 |
| Debtors turnover | 3.25 | 3.78 |
| EPS (₹) | 34.99 | 300.93 |
| Dividend per share (₹) | 0.00 | 0.00 |
| Book value per share (₹) | 152.01 | 1,205.82 |
To see the full year-wise statements and ratios of Q-Line Biotech Limited, buy the company report.
Board of directors of Q-Line Biotech Limited
Q-Line Biotech has 11 current directors and 6 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Kuldeep Chowdhry | Whole-Time Director | 12 Jan 2015 | 11 Years 9 Months | Current |
| Ajay Kumar Mahanty Also directs: Q-Line Nutraceuticals Private Limited | Whole-Time Director | 12 Jan 2015 | 11 Years 9 Months | Current |
| Abhay Agrawal | Director | 12 Jan 2015 | 11 Years 9 Months | Current |
| Amita Garg Also directs: Q-Line Healthcare Private Limited, Heidelco Medicore Private Limited, Asg Buildtech Private Limited and 3 more | Director | 10 Nov 2010 | 15 Years 11 Months | Current |
| Saurabh Garg Also directs: Q-Line Healthcare Private Limited, Heidelco Medicore Private Limited, Asg Buildtech Private Limited and 5 more | Managing Director | 10 Nov 2010 | 15 Years 11 Months | Current |
| Pravir Kumar Also directs: Oxrad Consultant LLP, Racl Geartech Limited | Director | 08 May 2025 | 1 Years 5 Months | Current |
Auditor
Q-Line Biotech Limited is audited by MAYANK MEHROTRA & ASSOCIATES for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| MAYANK MEHROTRA & ASSOCIATES | FY 2023 | 022941C |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 28 Apr 2026 | 101300412 | Others | ₹7.5 Cr | Open | |
| 15 Dec 2025 | 101210820 | Others | ₹15 Cr | Open | |
| 27 Nov 2025 | 101193879 | Others | ₹35.8 Cr | Open | |
| 12 Nov 2025 | 101210818 | Others | ₹9 Cr | Open | |
| 20 Mar 2024 | 100907646 | Others | ₹36 Cr | Open |
To see the full charge records of Q-Line Biotech Limited, buy the company report.
Total charge records: 16 View all charges
Deals & funding
Q-Line Biotech Limited has 9 deals on record (3 funding rounds, 3 secondary share transfers, 1 rights issue), with disclosed funding of ₹28.82 Cr; the latest was in May 2026.
Deals on record (5 of 9)
| When | Deal | Amount | Parties |
|---|---|---|---|
| May 2026 | IPO | ₹214.49 Cr | Investors: Sanshi Fund, Innovative Vision Fund, HDFC Bank Limited |
| May 2026 | Funding round | ₹27.44 Cr | Investors: Calliope Capital Advisors LLP , Sahastraa Advisors Private Limited , Deepak Malik Occupation Private Sector, an individual |
| Sep 2025 | Rights issue | ₹52.5 Lakh | Investors: 4 individuals |
| Sep 2025 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Jun 2025 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: 2 individuals |
To see the full deal history of Q-Line Biotech Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Q-Line Biotech Limited has 13 court cases on record: 6 filed by Q-Line Biotech, 7 filed against it. 5 cases are pending and 8 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 10 | 4 | 5 |
| High courts | 3 | 3 | 0 |
Cases on record (5 of 13)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Lucknow, Uttar Pradesh | Criminal case | Filed by the company against Speedbio India Private Limited and Other | Pending |
| Allahabad High Court | Writ petition | Filed against the company by Transasia Bio-Medicals Ltd. Thru. Auth. Representative Mr. Ajay Kumar Shukla (Assistant Manager) | Disposed |
| District court, Lucknow, Uttar Pradesh | Criminal case | Filed against the company by State of Up | Pending |
| District court, Lucknow, Uttar Pradesh | Criminal case | Filed by the company against M/S Riddhi Siddhi Enterprises Through Praveen Kumar | Pending |
| District court, Lucknow, Uttar Pradesh | Criminal case | Filed by the company against Medicinal Biotech Limited | Pending |
To see the full case history of Q-Line Biotech Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Q-Line Biotech Limited has 3 MSME Form 1 returns on record between 2015 and 2024, listing 24 overdue payments to 23 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 23)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| an individual supplier | |||
| an individual supplier | |||
| an individual supplier | |||
| an individual supplier |
To see the full MSME payment records of Q-Line Biotech Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Q-Line Biotech has 1 associated company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
Employees & EPFO
Q-Line Biotech Limited has a workforce of 219 employees on its EPFO records as of Mar 30, 2024, across 1 active EPFO establishment.
GST
Q-Line Biotech has 5 GST registrations: 4 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 09AAFCP9672B1Z6 | Uttar Pradesh | Active | 01 Jul 2017 |
| 07AAFCP9672B1ZA | Delhi | Active | 01 Jul 2017 |
| 19AAFCP9672B1Z5 | West Bengal | Active | 04 Sep 2019 |
| 21AAFCP9672B1ZK | Odisha | Active | 27 Jul 2021 |
To see the full GST registrations and return filing status of Q-Line Biotech Limited, buy the company report.
Recent activity
Q-Line Biotech Limited has 17 board changes on record since 2010: 11 appointments and 6 cessations. The latest: Jai Prakash Singh was appointed as Director on 01 Aug 2025.
36 earlier events are in the company report.
Frequently asked questions
Q-Line Biotech is an active public limited company based in Lucknow, Uttar Pradesh, India. The company works in medical equipment retail and distribution, within the healthcare industry. It was incorporated on 10 November 2010 (16+ years old) and is registered under CIN U74120UP2010PLC042528. Listed on NSE: QLINE.
Q-Line Biotech reported revenue of ₹341.74 Cr for FY 2025-26 (up 8.9% YoY) based on consolidated financials.
Q-Line Biotech has 11 current directors:
- Saurabh Garg - Managing Director
- Kuldeep Chowdhry - Whole-Time Director
- Ajay Kumar Mahanty - Whole-Time Director
- Prabhakara Subraya Yethadka - Whole-Time Director
- Abhay Agrawal - Director
- Amita Garg - Director
- Pravir Kumar - Director
- Rohit Nandan - Director
- Abhishek Mishra - Director
- Jai Prakash Singh - Director
- Ayush Garg - Director
The latest financial statements of Q-Line Biotech on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Q-Line Biotech is 09AAFCP9672B1Z6, registered in Uttar Pradesh. The company has 5 GST registrations in all, of which 4 are active and 1 is cancelled or inactive. Other active GSTINs include 07AAFCP9672B1ZA (Delhi), 19AAFCP9672B1Z5 (West Bengal), 21AAFCP9672B1ZK (Odisha).
The CIN (Corporate Identification Number) of Q-Line Biotech is U74120UP2010PLC042528. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Q-Line Biotech is a listed company as per MCA records. Its shares are listed on NSE (symbol: QLINE).
Q-Line Biotech has 13 court cases on record: 6 filed by the company and 7 filed against it. 5 are pending. Most are in the district courts.
Q-Line Biotech was incorporated on 10 November 2010, making it 16+ years old. It is registered with the Registrar of Companies, Uttar Pradesh.
Q-Line Biotech has 9 deals on record (3 funding rounds, 3 secondary share transfers, 1 rights issue), with disclosed funding of ₹28.82 Cr; the latest was in May 2026.
Jai Prakash Singh was appointed as Director on 01 Aug 2025. Saurabh Garg ceased to be Director on 31 Jul 2025. Abhishek Mishra was appointed as Director on 08 May 2025. Q-Line Biotech has 17 board changes on record in total.